Is chloramphenicol making a comeback?

Isr Med Assoc J. 2010 Jun;12(6):371-4.

Abstract

Background: Due to increasing antimicrobial resistance there has been renewed interest in old drugs that have fallen into disuse because of toxic side effects.

Objectives: To evaluate the susceptibility profile, in our hospital, of Enterobacteriaceae and Streptococcus pneumoniae isolates to chloramphenicol and to compare them with the susceptibility to amoxicillin-clavulanate.

Methods: All isolates of Enterobacteriaceae and S. pneumoniae recovered in our lab during a one year period were tested for susceptibility to chloramphenicol and amoxicillin-clavulanate or penicillin, respectively.

Results: Of 413 Enterobacteriaceae isolates, 182 (44.1%) were resistant to amoxicillin-clavulanate, but only 76 (18.4%) were resistant to chloramphenicol. Of 189 isolates of S. pneumoniae, 4 (2.1%) were highly resistant to penicillin and 73 (38.8%) were partially resistant, while only 2 (1.1%) were resistant to chloramphenicol. None of the 24 S. pneumoniae isolates causing invasive diseases exhibited resistance to chloramphenicol

Conclusions: In an era of increasing resistance to many antibiotic preparations, chloramphenicol might have a role in the treatment of intraabdominal and respiratory tract infections.

MeSH terms

  • Amoxicillin-Potassium Clavulanate Combination / pharmacology
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Chloramphenicol / pharmacology*
  • Chloramphenicol / therapeutic use
  • Enterobacteriaceae / drug effects
  • Humans
  • Microbial Sensitivity Tests
  • Respiratory Tract Infections / drug therapy
  • Streptococcus pneumoniae / drug effects

Substances

  • Anti-Bacterial Agents
  • Chloramphenicol
  • Amoxicillin-Potassium Clavulanate Combination